MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/14787210.2026.2669583

Медицинская библиотека · Expert review of anti-infective therapy · 2026

Metabolic outcomes of bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir/lamivudine in treatment-naïve people living with HIV: a 48-week retrospective study.

Guo Yifan, Fu Jiantao, Wang Jingxia, Xing Lulu, Li Jialu, Gao Chengyu, Zhao Yining, Li Qinlan, Ding Yi, Xiao Jiang, Zhao Hongxin

СтатьяСравнительное исследованиеПеревод в очереди

Аннотация

BACKGROUND

Although the high efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir/lamivudine (DTG/3TC) in treatment-naïve people living with HIV (PLWH) have been well established, their metabolic effects remain a concern.

RESEARCH DESIGN AND

METHODS

We retrospectively analyzed 499 treatment-naïve PLWH who initiated BIC/FTC/TAF or DTG/3TC at Beijing Ditan Hospital between January 2021 and December 2023 to compare metabolic outcomes over a 48-week follow-up period.

RESULTS

Compared to DTG/3TC, the BMI at week 48 was higher in participants receiving BIC/FTC/TAF (24.65 vs. 23.14 kg/m2, p = 0.023) after propensity score matching, with a greater increase from baseline (+1.10 vs. +0.71 kg/m2, p = 0.011). PLWH receiving BIC/FTC/TAF exhibited an increase in uric acid over 48 weeks (median change 5 μmol/L vs. -6 μmol/L, adjusted change p = 0.034). No significant between-group differences were observed in the changes of lipid, glucose and renal parameters over 48 weeks. Both regimens achieved similar virologic suppression (95.5% vs. 94.5%, p = 0.857) and comparable CD4 recovery (+188 vs. +173 cells/μL, p = 0.726).

CONCLUSION

In this cohort of treatment-naïve PLWH, initiation of BIC/FTC/TAF or DTG/3TC achieved comparable metabolic outcomes, immunologic and virologic after 48 weeks, while BIC/FTC/TAF was associated with significantly increases in BMI.

Для цитирования: Guo Yifan, Fu Jiantao, Wang Jingxia, Xing Lulu, Li Jialu, Gao Chengyu, Zhao Yining, Li Qinlan, Ding Yi, Xiao Jiang, Zhao Hongxin. Metabolic outcomes of bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir/lamivudine in treatment-naïve people living with HIV: a 48-week retrospective study.. Expert review of anti-infective therapy. 2026. DOI: 10.1080/14787210.2026.2669583.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.